Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Marik

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2022
Correction to: Preclinical development of ZED8, an <sup>89</sup>Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapyAnnie Ogasawara, James R Kiefer, Herman Gill, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 21, 2022
Preclinical development of ZED8, an <sup>89</sup>Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapyAnnie Ogasawara, James R Kiefer, Herman Gill, et al.
Nature Communications|June 5, 2026
Development of LRRC15-binding disulfide-constrained peptides for PET imaging of cancer-associated fibroblastsBenjamin J Tombling, Fei Cai, Timothy J Wendorff, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2022
Correction to: Preclinical development of ZED8, an <sup>89</sup>Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapyAnnie Ogasawara, James R Kiefer, Herman Gill, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 21, 2022
Preclinical development of ZED8, an <sup>89</sup>Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapyAnnie Ogasawara, James R Kiefer, Herman Gill, et al.
Nature Communications|June 5, 2026
Development of LRRC15-binding disulfide-constrained peptides for PET imaging of cancer-associated fibroblastsBenjamin J Tombling, Fei Cai, Timothy J Wendorff, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Pageof 6